Eli Lilly completes its takeover of Dermira, Novartis and the NHS strike an ‘innovative’ cardiovascular deal, GSK’s CEO hopes to get six new drug approvals in the next year, and Aberdeen University’s Elasmogen announces it’s secured follow-on equity investment.
Interested in Star’s innovative outsourcing and resourcing solutions?
Contact Operations Director, Mark Ward, on 07872 105 540 or email firstname.lastname@example.org.
On the hunt for a new role, or just curious?
Visit our candidate page, submit your CV to email@example.com, or give our offices a ring!
Novartis has announced plans to partner with the NHS in a “world-first” approach to addressing cardiovascular disease (CVD).
Eli Lilly has kicked off the new year with a $1.1bn takeover of dermatology specialist Dermira, setting the pace for pharma M&A as we enter a new decade.
Genomics England and Illumina have jointly announced a new agreement, which will see them deliver up to 300,000 whole genome equivalents over the next five years, with an option to increase to 500,000.
GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year.
Aberdeen University spin-out Elasmogen has announced the securing of follow-on equity investment from Deepbridge Capital totalling £2 million, taking the company’s total investment in Elasmogen to £3.15 million.
While you’re here…
…and are interested in our content, why not sign up to our newsletter?
It’s just below here.